Carlos A Lopez-Garcia1, Victor Lopez-Rivera2, Antonio Dono3, Sergio Salazar-Marioni2, Jorge E Novo4, Sunil A Sheth2, Leomar Y Ballester5, Yoshua Esquenazi6. 1. Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA. 2. Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX, USA. 3. Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center at Houston, Houston, TX, USA. 4. Department of Pathology and Laboratory Medicine Northwestern, Chicago, IL, USA. 5. Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA; Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center at Houston, Houston, TX, USA; Memorial Hermann Hospital, Houston, TX, USA. Electronic address: Leomar.Y.Ballester@uth.tmc.edu. 6. Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center at Houston, Houston, TX, USA; Memorial Hermann Hospital, Houston, TX, USA; Center of Precision Health, School of Biomedical Informatics, McGovern Medical School, the University of Texas Health Science Center at Houston, Houston, TX, USA. Electronic address: Yoshua.EsquenaziLevy@uth.tmc.edu.
Abstract
BACKGROUND: Prior reports demonstrate the expression of estrogen and progesterone receptors in high-grade gliomas (HGGs), but the relationship between hormone receptor-positive disease and risk of HHGs in patients with breast cancer (BC) remains uncharacterized. METHODS: Using the SEER 18 registries (2000-2017), we examined the temporal trend of the incidence of HGGs and BC. The standardized incidence ratio was calculated to assess the risk of subsequent HGG in BC patients. RESULTS: During the study period, the incidence of BC and HGGs remained comparable for men and women. Among 976,134 patients with BC, we found a decreased incidence of HGGs in females, but not in males. Female BC patients with hormone receptor-positive disease were at a lower risk of developing glioblastoma and anaplastic astrocytoma. CONCLUSION: Our study findings allude to the protective role of hormone exposure in the development of HGGs, which may lead to the development of therapies targeting hormonal pathways. Published by Elsevier Ltd.
BACKGROUND: Prior reports demonstrate the expression of estrogen and progesterone receptors in high-grade gliomas (HGGs), but the relationship between hormone receptor-positive disease and risk of HHGs in patients with breast cancer (BC) remains uncharacterized. METHODS: Using the SEER 18 registries (2000-2017), we examined the temporal trend of the incidence of HGGs and BC. The standardized incidence ratio was calculated to assess the risk of subsequent HGG in BC patients. RESULTS: During the study period, the incidence of BC and HGGs remained comparable for men and women. Among 976,134 patients with BC, we found a decreased incidence of HGGs in females, but not in males. Female BC patients with hormone receptor-positive disease were at a lower risk of developing glioblastoma and anaplastic astrocytoma. CONCLUSION: Our study findings allude to the protective role of hormone exposure in the development of HGGs, which may lead to the development of therapies targeting hormonal pathways. Published by Elsevier Ltd.
Authors: Jinyou Liu; Gangadhara R Sareddy; Mei Zhou; Suryavathi Viswanadhapalli; Xiaonan Li; Zhao Lai; Rajeshwar R Tekmal; Andrew Brenner; Ratna K Vadlamudi Journal: Cancer Res Date: 2018-04-16 Impact factor: 12.701